Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00439400 · ClinicalTrials.gov registry record · Phase 2
A Study of ALTY-0501 for the Treatment of Dry Eye Administered 4 Times a Day for a 56 Day Period
A Phase 2 study of Dry Eye, sponsored by Alacrity Biosciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 160
- Enrollment target
- 1
- Study location
NCT00439400 is a Phase 2 study of Dry Eye that has completed, run by Alacrity Biosciences. The registered enrollment target is 160 participants, above the 92-participant average among 41 other Dry Eye trials with a reported enrollment target (74% higher). The trial reports 1 study location across 1 state.
The verdict
NCT00439400, a Phase 2 study of Dry Eye, has completed, sponsored by Alacrity Biosciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 160 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective of this study is to assess the safety and efficacy of doxycycline 0.025% (ALTY-0501) ophthalmic solution for the treatment of dry eye using the Controlled Adverse Environment (CAE) Model.
Conditions Studied
Interventions
- DRUG placebo
- DRUG doxycycline
Study Locations (1)
Massachusetts
- Ophthalmic Research Associates - Andover
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2007-02 |
| Est. Completion | 2007-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00439400
The ClinicalTrials.gov registry entry for NCT00439400 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 92-participant average among 41 other Dry Eye trials with a reported enrollment target (74% higher). The listed sponsor is Alacrity Biosciences, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Dry Eye appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT00439400 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00439400 about?
NCT00439400 is a clinical study titled "A Study of ALTY-0501 for the Treatment of Dry Eye Administered 4 Times a Day for a 56 Day Period". The objective of this study is to assess the safety and efficacy of doxycycline 0.025% (ALTY-0501) ophthalmic solution for the treatment of dry eye using the Controlled Adverse Environment (CAE) Model.
What is the current status of trial NCT00439400?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 160 participants. The study started on 2007-02. Estimated completion is 2007-08.
What conditions does trial NCT00439400 study?
This clinical trial studies the following conditions: Dry Eye.
What interventions are being tested in trial NCT00439400?
The interventions under investigation include: placebo (DRUG), doxycycline (DRUG).
Who is sponsoring clinical trial NCT00439400?
This trial is sponsored by Alacrity Biosciences, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00439400 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dry Eye
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in the Treatment of Dry Eye
RECRUITING · Phase 2
-
An Eight-Week Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in the Treatment of Dry Eye
RECRUITING · Phase 2
-
Phase 2b Controlled Study of Dosing Techniques - Part B
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Assess the Safety and Efficacy of ECF843 vs Vehicle in Subjects With Dry Eye Disease
COMPLETED · Phase 2
-
An 8-week Study to Evaluate Safety and Efficacy of NGF Eye Drops Solution Versus Vehicle in Patients With Dry Eye
COMPLETED · Phase 2
-
Can Pregabalin Reduce the Frequency and Severity of Dry Eye Symptoms After Laser-assisted in Situ Keratomileusis?
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.